Navigation Links
Cellectis bioresearch Appoints Wako as Exclusive Distributor of its Genome Customization Solutions in Japan
Date:5/18/2011

PARIS and OSAKA, Japan, May 18, 2011 /PRNewswire/ -- Cellectis bioresearch, a subsidiary of Cellectis (Alternext: ALCLS) and genome customization specialist, has appointed Wako Pure Chemical Industries as its distributor in Japan for the Company's broad portfolio of research products and services, including the recently launched TALEN(1) Access™. Wako Pure Chemical Industries is a leading distributor of research products in Japan.

"In February 2011, we launched our revolutionary rapid, custom-designed TALEN service that enables access to genome customization tools to a large audience of life science researchers, due to its affordable price,” said Luc Selig, VP Sales & Marketing at Cellectis bioresearch. "We are now targeting rapid global distribution and Japan is a major player in life science research. Wako will allow us to enter this important market effectively, thanks to its key position."

Cellectis bioresearch's current portfolio includes more than 200 product references that address the genome customization requirements of life science researchers. In the last 12 months, Cellectis bioresearch has deployed its own sales force in Europe and the USA and has appointed agents and distributors in Canada and India. Online purchase is also available through the Cellectis bioresearch website.

About Cellectis bioresearch

Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides life science researchers with ready- and easy-to-use tools for genome customization. These tools, based on sequence specific nucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional studies.

The kits can be purchased online from www.cellectis-bioresearch.com. More information on the website.

About Cellectis

Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including human therapeutics, bioresearch and agriculture. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.

More information at www.cellectis.com  

Follow Cellectis on Twitter at www.twitter.com/cellectis

About Wako Pure Chemical Industries, Ltd.

Wako Pure Chemical Industries, Ltd., which is headquartered at Osaka (Japan) is the Japan's largest manufacture of laboratory chemical, specialty chemicals, and diagnostic reagents. Wako was founded in 1922 and currently has 1,440 employees, locating offices in all over in Japan, Europe and US. Wako contribute to the development of science and technology and create a prosperous future.

For further information, please go to: http://www.wako-chem.co.jp/english/

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

(1) TALEN: Transcription Activator-Like Effector Nucleases


'/>"/>
SOURCE Cellectis
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cellectis and Caisse des Depots Sign Agreement on a Project for the Industrial Development of iPS Cells
2. Cellectis Receives Payment for License to Homologous Recombination Patents
3. Cellectis Publishes 2010 Financial Results
4. Cellectis and the Etablissement Francais du Sang Launch StemRed, a Program to Produce Red Blood Cells From Stem Cells
5. Cellectis bioresearch First to Launch Revolutionary Custom TAL Nuclease Service
6. Cellectis Meganuclease Technology Used to Efficiently Prevent Viral Infection
7. Cellectis bioresearch Announces the First TGCA Winner
8. Cellectis bioresearch Signs Non-Exclusive License With Evrogen for Access to Fluorescent Proteins
9. Cellectis Plant Sciences Licenses Plant Transformation Technology for Corn and Rice
10. Cellectis and the Center for iPS Cells Research and Application Enter Collaboration
11. Cellectis Plant Sciences Licenses Plant Transformation Technology From Midwest Oilseeds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2017)... , ... August 11, 2017 , ... Algenist continues to ... formulation unlocking collagen like never before. , Collagen is the key structural element ... market with Liquid Collagen™, which include: , First to ...
(Date:8/10/2017)... ... August 09, 2017 , ... Teachers from three Philadelphia ... August 14th through the 16th, the University City Science Center will kick off ... 2016, provides Philadelphia-based middle school educators an opportunity for professional development related to ...
(Date:8/10/2017)... Bahama (PRWEB) , ... August 09, 2017 , ... Okyanos ... will take place at the Pelican Bay Hotel in Freeport, Grand Bahama on September ... pre-registration is required. , With oversight from the Ministry of Health’s National Stem ...
(Date:8/10/2017)... ... August 10, 2017 , ... ... establishing Kinokuniya Company Ltd. as its exclusive sales representative for SPIE Journals in ... for the SPIE Digital Library in Japan. , “We look forward to expanding ...
Breaking Biology Technology:
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
Breaking Biology News(10 mins):